Clinical Trials · NCT01107717
Durability of Combination Therapy With Exenatide/Pioglitazone/Metformin vs. Conventional Therapy in New Onset T2DM
- Phase
- Phase 4
- Recruitment status
- Completed
- Sponsor
- The University of Texas Health Science Center at San Antonio
- Enrollment
- 318
- Start date
- Jan 2009
- Locations
- 1 site, United States
- Primary endpoint
- HbA1c Level